Meningococcal conjugate vaccine for healthy adults aged 19–55

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 2/3 interventional trial gives a single dose of the investigational EG-MCV4 meningococcal conjugate vaccine to healthy adults aged 19–55, with Menveo included as a comparator. Eligible participants provide informed consent, attend scheduled in-person visits at the study site, and are contacted by phone for follow-up. The study collects blood samples to measure antibody responses to meningococcal groups A, C, W-135, and Y and records adverse events to monitor safety. Outcomes will compare immunogenicity and safety signals between EG-MCV4 and the licensed comparator.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Healthy males and females aged 19 to 55 years.
* Individuals who have been fully informed about the clinical trial, understand the details, and voluntarily agree to participate by providing written informed consent.
* Individuals who are available for all scheduled visits, including phone calls and in-person appointments, for the duration of the study.

Exclusion Criteria:

* History of prior disease caused by N. meningitidis.
* Contact with a person infected with N. meningitidis within 60 days of screening.
* Prior receipt of a meningococcal vaccine or a vaccine containing a meningococcal antigen.
* History of or planned vaccination with any other vaccine within 4 weeks before or after administration of the investigational product.
* History of fever (≥ 38°C) within 3 days of screening, or a history of a significant acute infectious disease within 7 days of screening, or a chronic infectious disease within 4 weeks of screening.
* History of Hepatitis B or C at the time of screening.
* Presence of any significant acute, chronic, or progressive disease that, in the opinion of the investigator, could interfere with the conduct or completion of the study.
* History of malignancy or high-risk malignant disease within 5 years before the investigational product administration.
* History of epilepsy, progressive neurological disease, or Guillain-Barré Syndrome.
* History of anaphylaxis.
* History of systemic urticaria within 5 years of the investigational product administration.
* Hypersensitivity to the active substance, diphtheria toxoid (CRM197), or any other excipient, or a history of a life-threatening reaction to a vaccine containing similar components.
* Hypersensitivity to the investigational vaccine, any of its components, or latex.
* History of any therapy that could affect the immune system within 6 months of screening.
* History of immunodeficiency disease, or a family history of such a disease.
* Receipt of any parenteral immunoglobulin preparation, blood product, or plasma derivatives within 90 days of screening, or planned administration during the study period.
* History of platelet-related or hemorrhagic disorders or a history of excessive bleeding or bruising after intramuscular injection or venipuncture.
* Current treatment with anticoagulants or new antiplatelet agents.
* History of organ or bone marrow transplantation.
* Suspected history of drug or alcohol abuse within 1 year before the investigational product administration.
* Individuals unwilling to use a medically acceptable method of contraception for the duration of the clinical trial.
* Pregnant or lactating women.
* Receipt or planned receipt/application of another investigational drug or medical device within 6 months prior to study participation.
* Presence of a significant abnormality on a screening test, or any other reason that, in the opinion of the investigator, makes the individual unsuitable for the study.

Where it's running

• The Catholic University of Eunpyeong St.Mary's Hospital
  Seoul, South Korea Recruiting

Study contacts

• Study coordinator: Jooyoung Park
• Email: jypark@eyegene.co.kr
• Phone: +82-2-322-1687

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Vaccination safety and immune response in adults with HIV

  This study is testing how safe and effective meningococcal and pneumococcal vaccines are for adults with HIV who are on treatment.

  Recruiting Phase 4 Hvidovre University Hospital · Hvidovre · NCT04875819

• Meningococcal vaccine for children 12–23 months old (Group ACYW135)

  This study tests whether the new Group ACYW135 meningococcal vaccine in healthy children aged 12 to 23 months can provoke a similar immune response and has an acceptable safety profile compared with a licensed vaccine.

  Recruiting at 2 sites Phase 3 Sinovac Biotech Co., Ltd · Nanning, Guangxi and 1 other locations · NCT07505836

• Group ACYW135 meningococcal vaccine in children 6-11 months

  This trial tests whether the investigational meningococcal vaccine in healthy infants aged 6 to 11 months can provoke a strong immune response with good safety compared with a licensed vaccine.

  Recruiting at 2 sites Phase 3 Sinovac Biotech Co., Ltd · Nanning, Guangxi and 1 other locations · NCT07505823

• Meningococcal vaccine in infants aged 3-5 months

  This trial tests a new group ACYW135 meningococcal vaccine in healthy babies aged 3 to 5 months to see if it triggers a strong immune response and how safe it is, with a booster given at 12 months.

  Recruiting at 2 sites Phase 3 Sinovac Biotech Co., Ltd · Nanning, Guangxi and 1 other locations · NCT07505810

• National survey on bacterial meningitis in children

  This study is trying to learn more about bacterial meningitis in children by looking at which bacteria are causing it and how things have changed since the introduction of vaccines.

  Recruiting Association Clinique Thérapeutique Infantile du val de Marne · Créteil · NCT04664569

• Is its immune response and safety in babies and toddlers when given a meningococcal vaccine in China

  This study tests whether the MenACYW conjugate vaccine safely produces an immune response in healthy infants and toddlers in China, compared with locally licensed vaccines.

  Recruiting at 8 sites Phase 3 Sanofi · Huanggang and 7 other locations · NCT07710872

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.